Table 2 Serum interleukin (IL-22 and IL-33) concentrations stratified by age group, gender, and body mass index in COVID-19 cases, controls, and all participants (patients plus controls)
Group | Median (IQR); pg/mL | |||||
|---|---|---|---|---|---|---|
COVID-19; n = 90 | Controls; n = 90 | All; n = 180 | ||||
IL-22 | IL-33 | IL-22 | IL-33 | IL-22 | IL-33 | |
Age; year | ||||||
20–39 | 18.9 (18.0–19.3) | 40.1 (36.3–43.3) | 13.9 (12.7–14.9) | 24.0 (23.0–28.0) | 16.8 (13.8–18.8) | 31.4 (23.5–40.2) |
40–65 | 18.5 (18.0–19.2) | 37.7 (34.9–42.0) | 13.9 (12.1–15.5) | 24.1 (23.0–25.9) | 17.0 (13.7–18.5) | 30.7 (23.9–39.3) |
p-value | 0.422 | 0.379 | 0.913 | 0.974 | 0.938 | 0.911 |
Gender | ||||||
Male | 18.5 (18.0–19.2) | 39.3 (36.4–43.5) | 14.1 (12.7–14.9) | 24.0 (23.0–26.2) | 16.6 (13.8–18.4) | 29.8 (23.7–39.6) |
Female | 19.1 (18.1–19.5) | 37.4 (35.3–42.1) | 13.8 (12.1–15.2) | 24.1 (22.6–26.1) | 17.2 (13.5–19.1) | 33.0 (24.1–39.9) |
p-value | 0.141 | 0.352 | 0.585 | 0.797 | 0.518 | 0.558 |
BMI | ||||||
NWT | 19.2 (18.1–19.5) | 39.5 (34.9–43.4) | 13.7 (12.4–15.2) | 25.1 (23.3–28.9) | 16.3 (13.5–19.1) | 29.8 (24.1–38.0) |
O/O | 18.5 (17.9–19.2) | 37.8 (36.2–42.7) | 14.1 (12.1–14.9) | 23.8 (22.1–25.8) | 17.2 (14.1–18.5) | 32.4 (23.7–39.7) |
p-value | 0.04 | 0.981 | 0.517 | 0.072 | 0.868 | 0.874 |